Insights into the Genetic Basis of the Renal Cell Carcinomas from The Cancer Genome Atlas

The renal cell carcinomas (RCC), clear cell, papillary, and chromophobe, have recently undergone an unmatched genomic characterization by The Cancer Genome Atlas. This analysis has revealed new insights into each of these malignancies and underscores the unique biology of clear cell, papillary, and chromophobe RCC. Themes that have emerged include distinct mechanisms of metabolic dysregulation and common mutations in chromatin modifier genes. Importantly, the papillary RCC classification encompasses a heterogeneous group of diseases, each with highly distinct genetic and molecular features. In conclusion, this review summarizes RCCs that represent a diverse set of malignancies, each with novel biologic programs that define new paradigms for cancer biology. Mol Cancer Res; 14(7); 589–98. ©2016 AACR.

[1]  Ximing J. Yang,et al.  Genomic expression and single-nucleotide polymorphism profiling discriminates chromophobe renal cell carcinoma and oncocytoma , 2010, BMC Cancer.

[2]  M. Ladanyi,et al.  Xp11 Translocation Renal Cell Carcinoma in Adults: Expanded Clinical, Pathologic, and Genetic Spectrum , 2007, The American journal of surgical pathology.

[3]  Aleix Prat Aparicio.  Comprehensive molecular portraits of human breast tumours , 2012 .

[4]  G. Kovacs,et al.  Low chromosome number in chromophobe renal cell carcinomas , 1992, Genes, chromosomes & cancer.

[5]  A. Ravaud,et al.  First-line treatment with sunitinib for type 1 and type 2 locally advanced or metastatic papillary renal cell carcinoma: a phase II study (SUPAP) by the French Genitourinary Group (GETUG)†. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[6]  J. Brugarolas.  Molecular genetics of clear-cell renal cell carcinoma. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  D. Grignon,et al.  Multilocular Cystic Renal Cell Carcinoma: Similarities and Differences in Immunoprofile Compared With Clear Cell Renal Cell Carcinoma , 2012, The American journal of surgical pathology.

[8]  P. Tamboli,et al.  Vascular endothelial growth factor‐targeted therapy for the treatment of adult metastatic Xp11.2 translocation renal cell carcinoma , 2010, Cancer.

[9]  M. Kattan,et al.  ClearCode34: A prognostic risk predictor for localized clear cell renal cell carcinoma. , 2014, European urology.

[10]  Soroush Rais-Bahrami,et al.  Molecular genetics and cellular features of TFE3 and TFEB fusion kidney cancers , 2014, Nature Reviews Urology.

[11]  Steven J. M. Jones,et al.  Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma. , 2016, The New England journal of medicine.

[12]  E. Wallen,et al.  Meta-analysis of clear cell renal cell carcinoma gene expression defines a variant subgroup and identifies gender influences on tumor biology. , 2012, European urology.

[13]  Han Liu,et al.  Clinical and pathologic impact of select chromatin-modulating tumor suppressors in clear cell renal cell carcinoma. , 2013, European urology.

[14]  S. Signoretti,et al.  The Role of Aberrant VHL/HIF Pathway Elements in Predicting Clinical Outcome to Pazopanib Therapy in Patients with Metastatic Clear-Cell Renal Cell Carcinoma , 2013, Clinical Cancer Research.

[15]  Tsutomu Ohta,et al.  Cancer related mutations in NRF2 impair its recognition by Keap1-Cul3 E3 ligase and promote malignancy , 2008, Proceedings of the National Academy of Sciences.

[16]  J. Patard,et al.  ICUD-EAU International Consultation on Kidney Cancer 2010: treatment of metastatic disease. , 2011, European urology.

[17]  Bin Tean Teh,et al.  A molecular classification of papillary renal cell carcinoma. , 2005, Cancer research.

[18]  Gabor T. Marth,et al.  Integrative Annotation of Variants from 1092 Humans: Application to Cancer Genomics , 2013, Science.

[19]  J. Ochocki,et al.  Fructose-1, 6-bisphosphatase opposes renal carcinoma progression , 2014, Nature.

[20]  D. Hansel,et al.  Morphologic and Molecular Characteristics of Bladder Cancer. , 2015, Surgical pathology clinics.

[21]  Amnon Zisman,et al.  Cytogenetic and Molecular Tumor Profiling for Type 1 and Type 2 Papillary Renal Cell Carcinoma , 2009, Clinical Cancer Research.

[22]  N. Rioux-Leclercq,et al.  Prognostic value of histologic subtypes in renal cell carcinoma: a multicenter experience. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  D. Nanus,et al.  Genome-Wide Profiling of TRACK Kidneys Shows Similarity to the Human ccRCC Transcriptome , 2015, Molecular Cancer Research.

[24]  Benjamin J. Raphael,et al.  Multiplatform Analysis of 12 Cancer Types Reveals Molecular Classification within and across Tissues of Origin , 2014, Cell.

[25]  C. Sander,et al.  Adverse Outcomes in Clear Cell Renal Cell Carcinoma with Mutations of 3p21 Epigenetic Regulators BAP1 and SETD2: A Report by MSKCC and the KIRC TCGA Research Network , 2013, Clinical Cancer Research.

[26]  Nanami Gotoh.  Fundamentals of Medical Physiology , 2012, The Yale Journal of Biology and Medicine.

[27]  B. Delahunt,et al.  Clear Cell Tubulopapillary Renal Cell Carcinoma: A Study of 36 Distinctive Low-grade Epithelial Tumors of the Kidney , 2010, The American journal of surgical pathology.

[28]  Wanling Xie,et al.  Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  Rochelle L. Tiedemann,et al.  Dynamic reprogramming of DNA methylation in SETD2-deregulated renal cell carcinoma , 2015, Oncotarget.

[30]  G W Timm,et al.  Editorial Comment , 2001, International Journal of Impotence Research.

[31]  R. Deberardinis,et al.  The transcription factor HIF-1alpha plays a critical role in the growth factor-dependent regulation of both aerobic and anaerobic glycolysis. , 2007, Genes & development.

[32]  Ximing J. Yang,et al.  Disruption of tubular Flcn expression as a mouse model for renal tumor induction. , 2015, Kidney international.

[33]  P. Tamboli,et al.  Everolimus Versus Sunitinib Prospective Evaluation in Metastatic Non-Clear Cell Renal Cell Carcinoma (ESPN): A Randomized Multicenter Phase 2 Trial. , 2016, European urology.

[34]  Steven J. M. Jones,et al.  Comprehensive molecular characterization of clear cell renal cell carcinoma , 2013, Nature.

[35]  Joel S Parker,et al.  Variation in chromatin accessibility in human kidney cancer links H3K36 methyltransferase loss with widespread RNA processing defects , 2014, Genome research.

[36]  N. Sneige,et al.  The feasibility of gene expression profiling generated in fine‐needle aspiration specimens from patients with follicular lymphoma and diffuse large B‐cell lymphoma , 2005, Cancer.

[37]  Weili Lin,et al.  Alternate Metabolic Programs Define Regional Variation of Relevant Biological Features in Renal Cell Carcinoma Progression , 2016, Clinical Cancer Research.

[38]  Yuen-Li Chung,et al.  HIF overexpression correlates with biallelic loss of fumarate hydratase in renal cancer: novel role of fumarate in regulation of HIF stability. , 2005, Cancer cell.

[39]  Steven J. M. Jones,et al.  Genomic Classification of Cutaneous Melanoma , 2015, Cell.

[40]  R. Motzer,et al.  Treatment outcome with mTOR inhibitors for metastatic renal cell carcinoma with nonclear and sarcomatoid histologies. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[41]  W. Kaelin,et al.  Role of VHL gene mutation in human cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[42]  Chang S. Chan,et al.  The Genomic Landscape of Renal Oncocytoma Identifies a Metabolic Barrier to Tumorigenesis , 2015, Cell reports.

[43]  Martin L. Miller,et al.  Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer , 2015, Science.

[44]  Steven J. M. Jones,et al.  Comprehensive molecular portraits of human breast tumors , 2012, Nature.

[45]  J. Reeves,et al.  Pazopanib versus sunitinib in metastatic renal-cell carcinoma. , 2013, The New England journal of medicine.

[46]  Karl J. Dykema,et al.  CUL3 and NRF2 mutations confer an NRF2 activation phenotype in a sporadic form of papillary renal cell carcinoma. , 2013, Cancer research.

[47]  F. Waldman,et al.  Improved Identification of von Hippel-Lindau Gene Alterations in Clear Cell Renal Tumors , 2008, Clinical Cancer Research.

[48]  M. Smith.  Multilocular Cystic Renal Cell Carcinoma: Similarities and Differences in Immunoprofile Compared With Clear Cell Renal Cell Carcinoma , 2013 .

[49]  G. Kovacs,et al.  Mitochondrial and chromosomal DNA alterations in human chromophobe renal cell carcinomas , 1992, The Journal of pathology.

[50]  Jessica E. S. Shay,et al.  Effects of hypoxia and HIFs on cancer metabolism , 2012, International Journal of Hematology.

[51]  Lawrence A. Donehower,et al.  The somatic genomic landscape of chromophobe renal cell carcinoma. , 2014, Cancer cell.

[52]  Steven J. M. Jones,et al.  Comprehensive genomic characterization of squamous cell lung cancers , 2012, Nature.

[53]  Brian Keith,et al.  Differential Roles of Hypoxia-Inducible Factor 1α (HIF-1α) and HIF-2α in Hypoxic Gene Regulation , 2003, Molecular and Cellular Biology.

[54]  B. Delahunt,et al.  Papillary renal cell carcinoma: a clinicopathologic and immunohistochemical study of 105 tumors. , 1997, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

[55]  C. Sander,et al.  Tumor Genetic Analyses of Patients with Metastatic Renal Cell Carcinoma and Extended Benefit from mTOR Inhibitor Therapy , 2014, Clinical Cancer Research.

[56]  Wei Li,et al.  HIF-1α pathway: role, regulation and intervention for cancer therapy , 2015, Acta pharmaceutica Sinica. B.

[57]  David T. W. Jones,et al.  Signatures of mutational processes in human cancer , 2013, Nature.

[58]  Lisa N Kinch,et al.  Spectrum of diverse genomic alterations define non–clear cell renal carcinoma subtypes , 2014, Nature Genetics.

[59]  Steven J. M. Jones,et al.  Comprehensive molecular portraits of human breast tumours , 2013 .

[60]  C. Elie,et al.  Survival analysis of 130 patients with papillary renal cell carcinoma: prognostic utility of type 1 and type 2 subclassification. , 2007, Urology.

[61]  N. Grishin,et al.  Succination of Keap1 and activation of Nrf2-dependent antioxidant pathways in FH-deficient papillary renal cell carcinoma type 2. , 2011, Cancer cell.

[62]  W. Linehan,et al.  Novel mutations of the MET proto-oncogene in papillary renal carcinomas , 1999, Oncogene.

[63]  R. Figlin,et al.  Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. , 2007, The New England journal of medicine.

[64]  D. Cella,et al.  Randomized phase II trial of first-line treatment with sorafenib versus interferon Alfa-2a in patients with metastatic renal cell carcinoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[65]  V. Kaklamani,et al.  A genetic signature can predict prognosis and response to therapy in breast cancer: Oncotype DX , 2006, Expert review of molecular diagnostics.

[66]  W. Kaelin,et al.  The VHL/HIF axis in clear cell renal carcinoma. , 2013, Seminars in cancer biology.

[67]  D. Schadendorf,et al.  TERT Promoter Mutations in Familial and Sporadic Melanoma , 2013, Science.

[68]  David Piquemal,et al.  Of Mice and Men: Divergence of Gene Expression Patterns in Kidney , 2012, PloS one.

[69]  Brian Keith,et al.  Differential roles of hypoxia-inducible factor 1alpha (HIF-1alpha) and HIF-2alpha in hypoxic gene regulation. , 2003, Molecular and cellular biology.

[70]  D. Schadendorf,et al.  Highly Recurrent TERT Promoter Mutations in Human Melanoma , 2022 .

[71]  P. Carmeliet,et al.  Renal Cyst Formation in Fh1-Deficient Mice Is Independent of the Hif/Phd Pathway: Roles for Fumarate in KEAP1 Succination and Nrf2 Signaling , 2011, Cancer cell.

[72]  Stephen G Swisher,et al.  Nrf2 and Keap1 Abnormalities in Non–Small Cell Lung Carcinoma and Association with Clinicopathologic Features , 2010, Clinical Cancer Research.

[73]  Ximing J. Yang,et al.  An antioxidant response phenotype shared between hereditary and sporadic type 2 papillary renal cell carcinoma. , 2011, Cancer cell.

[74]  K. Clarke,et al.  Dysregulation of hypoxia pathways in fumarate hydratase-deficient cells is independent of defective mitochondrial metabolism. , 2010, Human molecular genetics.

[75]  Gyan Bhanot,et al.  Abstract 1996: Molecular stratification of clear cell renal cell carcinoma by consensus clustering reveals distinct subtypes and survival patterns , 2010 .

[76]  A. Ravaud,et al.  Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. , 2015, The New England journal of medicine.

[77]  P. Choyke,et al.  Mutations in the fumarate hydratase gene cause hereditary leiomyomatosis and renal cell cancer in families in North America. , 2003, American journal of human genetics.

[78]  Elizabeth M Webber,et al.  Oncotype DX tumor gene expression profiling in stage II colon cancer , 2010, PLoS currents.

[79]  A. Pappo,et al.  Pediatric renal cell carcinoma: clinical, pathologic, and molecular abnormalities associated with the members of the mit transcription factor family. , 2006, American journal of clinical pathology.